NextCure, Inc. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
NextCure, Inc. (parent company, ~$12.6M market cap) agreed to merge with Avere Therapeutics, Inc. via two-step merger structure. Avere equity valued at $250M; exchange ratio based on Parent Net Cash calculation and Company Valuation. Merger consideration: Avere stockholders receive Parent Common Stock (subject to Beneficial Ownership Limitation) and Pre-Funded Warrants for excess shares. Parent target cash: $0 (declining $450k/month after Nov 30, 2026). Contingent Value Rights (CVRs) distributed to Parent's pre-merger stockholders. Closing contingent on stockholder approvals, regulatory clearances, and minimum $150M concurrent investment.
Why this rating
Reverse merger transformational for $12.6M NextCure: ~$250M Avere valuation represents 20x+ expansion; material dilution offset by substantial asset base; regulatory/financing conditions create execution risk but deal structure protects both parties.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.